摘要
目的探讨孟鲁司特联合布地奈德预防及治疗婴幼儿毛细支气管炎后喘息的效果。方法选取2013年6月到2015年12月我院诊治的340例毛细支气管炎后喘息婴幼儿,根据随机信封抽签原则分为观察组与对照组,各170例。对照组给予布地奈德治疗,观察组给予孟鲁司特联合布地奈德治疗。两组均治疗7 d,记录治疗总有效率与临床症状恢复情况。结果治疗后,观察组与对照组的治疗总有效率分别为96.47%和81.76%,观察组的治疗总有效率明显高于对照组(P<0.05)。观察组的呼吸困难、咳嗽、发热等症状消失时间分别为(1.57±0.64)d、(4.24±1.34)d和(2.81±1.95)d,都明显短于对照组的(2.44±0.46)d、(6.14±1.94)d和(5.29±2.15)d(P<0.05)。结论孟鲁司特联合布地奈德预防及治疗婴幼儿毛细支气管炎后喘息能促进临床症状的改善,提高治疗效果,有良好的应用价值。
Objective To discuss and observe the effect of montelukast joint budesonide in the prevention and treatment of infant gasp after capillary bronchitis. Methods A total of 340 infants with gasp after capillary bronchitis treated in our hospital from June 2013 to December 2015 were divided into control group and observation group（170 cases respectively）by random envelope principle. The control group was treated with budesonide, and the observation group was treated with montelukast joint budesonide. The two groups were treated for 7 d, and the total efficiency of treatment and recovery of clinical symptoms were recorded. Results The total efficiency of treatment in the observation group（96.47%） was higher than the control group（81.76%）, and the difference was obvious（P〈0.05）. The die-out time of dyspnea, cough and fever in the observation group [（1.57±0.64） d,（4.24±1.34） d and（2.81±1.95） d respectively] was obviously shorter than those in the control group [（2.44±0.46） d,（6.14±1.94） d and（5.29±2.15） d respectively], and the differences were significant（P〈0.05）.Conclusion Montelukast joint budesonide in the prevention and treatment of infant gasp after capillary bronchitis can promote the improvement of the clinical symptoms, increase the efficacy and has good application value.
出处
《临床医学研究与实践》
2017年第33期113-114,共2页
Clinical Research and Practice
